Our results showed that the expression levels of the CDC20 gene were significantly elevated in prostate cancer, kidney cancer, bladder cancer, breast cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, lung cancer, liver cancer, uterine cancer, and pancreatic cancer. This evidence concerns the gene CDC20 and kidney cancer.